Early safety check for new kidney drug begins
NCT ID NCT02653014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and tolerability of a new drug called KBP-5074 in 26 adults, including healthy volunteers and those with mild to moderate kidney impairment. Researchers measured how the drug moves through the body and its effects on blood pressure and potassium levels. The goal was to gather information to help design larger future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research by Design, LLC
Evergreen Park, Illinois, 60805, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that boosts red blood cells help anemia in kidney disease?
- Predicting kidney trouble in older adults: a data-driven approach to clearer lab results
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Could delaying kidney implant during heart transplant reduce complications?
- Can a new tablet formulation improve how a kidney disease drug is absorbed?
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.